City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting May 6 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/city-therapeutics-presents-preclinical-data-next-generation Press Release Guest User Previous Previous City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting May 6 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/city-therapeutics-presents-preclinical-data-next-generation Press Release Guest User
